BusinessKannalife Sciences CEO Dean Petkanas to Provide Presentation on Industry Advancement at 2018 Cannabinoids in Medicine SummitBy Nasdaq OMXApr 27, 2018, 2:00 PM UTC
BusinessKannalife Sciences Announces Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat CTE and HEBy Nasdaq OMXFeb 29, 2016, 2:00 PM UTC
BusinessMedical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication Through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic EncephalopathyBy Nasdaq OMXFeb 18, 2016, 2:00 PM UTC
BusinessKannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”By Nasdaq OMXFeb 16, 2016, 4:16 PM UTC
BusinessKannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”By Nasdaq OMXFeb 16, 2016, 4:16 PM UTC
